Few among us would think highly of a leader who directed us to innovate on demand. After all, innovation is something that comes from a mysterious creative force that strikes like lightning to the fortunate inventor, bringing with it fame and fortune. Think Bill Hewlett and Dave Packard; Steve Jobs and Steve Wozniak; Bill Gates; Mark Zuckerberg; or Tim Berners-Lee (huh?) [1].
Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin’s lymphoma
The pharmacokinetic profiles of bendamustine and active metabolites were defined in patients with rituximab-refractory, relapsed indolent B-cell non-Hodgkin's lymphoma, and supported understanding of exposure-response relationships for efficacy and safety.
Dissolution modeling of bead formulations and predictions of bioequivalence for a highly soluble, highly permeable drug
The objective of this study was to assess the impact of observed in vitro dissolution rate differences on in vivo pharmacokinetics for two enteric-coated bead formulations...
Model hurricanes.
Although some meteorological modelers may disagree, it seems to me that models predicting development and movement of hurricanes are getting more and more accurate.
But…my projects are special.
Scientists in the field of pharmaceutical research and development face a most daunting challenge. Our understanding of the diseases we work to treat grows more complex and perplexing with each new published study. Take, for example, the gusher of information coming out on Alzheimer’s disease. How can research findings from genetics, neurology, nutrition, protein chemistry, pharmacology, and epidemiology (just to name a few) be tracked, sorted, and used?
Simulations Plus to Present at the Rodman & Renshaw Annual Global Investment Conference
Leading Provider of Simulation and Modeling Software for Pharmaceutical Discovery and Development Scheduled to Present on September 13, 2010; Rodman & Renshaw Annual Global Investment Conference NYC
What if the constants we take for granted are not really constant?
Seems like every time we learn something new, whether it is in biology or cosmology, we learn something else that just makes us sit back and say Wow. So it is with a recent story in The Economist about new information regarding one of the universal “constants” alpha.
Simulations Plus Reports Preliminary Revenues for Fourth Fiscal Quarter of FY2010
New Record Fiscal Year Follows Record 1st, 2nd and 3rd Quarters; Rodman & Renshaw Annual Global Investment Conference NYC
Beyond Filters: ADMET Risk™ for Multi-objective Drug Development
We calculated predictions for over 30 properties relevant to absorption, distribution, metabolism, excretion and toxicity (ADMET) for a large and pharmaceutically pertinent...
Kinda like standing in front of a development team, huh?
G.H. Hardy* said, “A mathematician, like a painter or a poet, is a maker of patterns. And just as in poetry and painting, the mathematician’s patterns must be beautiful. Beauty is the first test,” he said. “There is no permanent place in the world for ugly mathematics.”
Not too complicated for words.
Jackson Pollock’s Autumn Rhythm (seen here) is an example of a complex painting that can be grasped with a few moments of contemplation, according to Terry Teachout (links to a dead page) in the Wall Street Journal. Pollock worked during the mid 20th century, when nature was assumed to be random. However, as Robert Taylor (links to content that is no longer available) explained in a 2002 Scientific American article:
Shanghai: A Cacophony of People
Update: For another perspective on tech employment in the United States and China, see Andy Grove’s recent article in Bloomberg Businessweek.
The biowaivers extension for BCS Class III drugs: the effect of dissolution rate on on the bioequivalence of BCS Class III IR drugs predicted by computer simulation
The Biopharmaceutical Classification System (BCS) guidance issued by the FDA allows waivers for in vivo bioavailability and bioequivalence studies for immediate-release...
In Silico Classification of Major Clearance Pathways of Drugs with Their Physiochemical Parameters
Predicting major clearance pathways of drugs is important in understanding their pharmacokinetic properties in clinical use, such as drug-drug interactions and genetic...
Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects
Intravenous (IV) iron is used to treat iron-deficiency anemia in patients with chronic kidney disease (CKD). Ferumoxytol is a novel iron formulation administered rapidly as two IV boluses of 510 mg each. In this placebo-controlled, double-blind...
Improving productivity with model-based drug development: an enterprise perspective
The productivity of the pharma enterprise has fallen, as evidenced by a decline in regulatory submissions and less commercial success.